Gianluca Fuggetta - Mar 21, 2024 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role
Principal Accounting and Financial Officer
Signature
/s/ Matthias Alder, Attorney-In-Fact
Stock symbol
GANX
Transactions as of
Mar 21, 2024
Transactions value $
$0
Form type
4
Date filed
3/25/2024, 09:30 PM
Previous filing
Mar 27, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GANX Employee Stock Option (right to buy) Award $0 +50K $0.00 50K Mar 21, 2024 Common Stock 50K $4.37 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option shall vest 25% on March 21, 2025 and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.

Remarks:

Principal Accounting and Financial Officer